|1.||Kumar, Rakesh: 2 articles (01/2005 - 05/2004)|
|2.||Kleinman, Hynda K: 1 article (01/2005)|
|3.||Philp, Deborah: 1 article (01/2005)|
|4.||Stafford, Jeffrey: 1 article (01/2005)|
|5.||Green, Jeffrey E: 1 article (01/2005)|
|6.||Huh, Jung-Im: 1 article (01/2005)|
|7.||Cheung, Mui: 1 article (01/2005)|
|8.||Calvo, Alfonso: 1 article (01/2005)|
|9.||Hayashi, Toshiaki: 1 article (05/2004)|
|10.||Burger, Renate: 1 article (05/2004)|
01/27/2005 - "The antitumor effects of GW654652 were associated with reduced tumor vascularization and no apparent toxicity. "
01/27/2005 - "This is the first demonstration that a VEGF receptor inhibitor, GW654652, has a strong inhibitory effect on angiogenesis and tumor progression in a transgenic model of mammary cancer, suggesting that this is a useful approach for preclinical testing of such agents."
01/27/2005 - "GW654652 significantly decreased cell proliferation and induced apoptosis in human umbilical vein endothelial cells and M6 mammary tumor cells derived from C3(1)/Tag (Tag: simian virus 40 T-antigen) transgenic mice. "
01/27/2005 - "GW654652, an indazolylpyrimidine, is a VEGFRs tyrosine kinase inhibitor that dramatically reduces both angiogenesis and tumor cell growth in this model, as demonstrated using both in vitro and in vivo assays. "
01/27/2005 - "A profound inhibitory effect on tumor growth in the C3(1)/Tag transgenic model of human breast cancer was observed with oral administration of GW654652 as measured by delayed tumor onset, decreased multiplicity, reduced tumor volume, and extended animal survival. "
|3.||Breast Neoplasms (Breast Cancer)
|1.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||Interleukin-6 (Interleukin 6)
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|5.||Tumor Viral Antigens (Large T Antigen)